1. Gimsing P, Bjerrum OW, Brandt E, Ellegaard J, Evensen SA, Hansen MM, Hedenus M, Hippe E, Keldsen N, Palva I. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG) [see comments]. Br J Haematol 1991; 77(1):73-79.
2. Wisloff F, Gimsing P, Hedenus M, Hippe E, Palva I, Talstad I, Turesson I, Westin J. Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG). Eur J Haematol 1992; 48(2):70-74.
3. Keldsen N, Bjerrum OW, Dahl IM, Drivsholm A, Ellegaard J, Gadeberg O, Gimsing P, Gronvold T, Hansen MM, Hippe E. Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase III study. Nordic Myeloma Study Group (NMSG). Eur J Haematol 1993; 51(2):80-85.
4. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53(4):207-212.
5. Hjorth M, Holmberg E, Rodjer S, Taube A, Westin J. Patient accrual and quality of participation in a multicentre study on myeloma: a comparison between major and minor participating centres. Br J Haematol 1995; 91(1):109-115.
6. Hjorth M. Clinical trials in multiple myeloma. Treatment results and methodological aspects [Thesis]. Göteborg University, 1995.
7. Johnsen HE. Report from a Nordic workshop on CD34+ cell analysis: technical recommandations for progenitor cell enumeration in leukapheresis from multiple myeloma patients. Nordic Myeloma Study Group Laboratories. J Hematother 1995; 4(1):21-28.
8. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group Ann Intern Med 1996; 124(2):212-222.